Abstract

During the last few years, reports have appeared claiming that lufenuron diminished or even cured dermatophyte infections in cats and dogs. As these observations have a rather anecdotal character leading to some ambiguity in the literature, it was decided to test lufenuron in a generally accepted animal model for dermatomycotic infection. The test was carried out in guinea pigs artificially infected with Microsporum canis on scarified dorsal skin and orally treated with lufenuron (Program™). The efficacy of up to five doses of 80 mg/kg was assessed 7 and 14 days after the start of treatment. All animals failed to show any improvement in skin lesions as compared to the vehicle‐only treated animals. Clinical symptoms taken into account were scaling, crust formation, erythema, and exudation. Neither the number of treatments (one or five) nor the dose range (40 or 80 mg/kg) made any difference. Itraconazole, tested earlier under identical circumstances, resulted in a clear and consistent improvement at day 7 of the infection at a dose of 15 mg/kg, given either in one dose or spread over several days. The absence of antimycotic activity of lufenuron in this established animal model constitutes a significant element in the discussion on the antifungal potency of lufenuron and supports the fact that there is, as yet, no evidence that benzoylphenyl urea derivative compounds have an effect on chitin synthesis in fungi. Funding: J&J Pharmaceutical Research and Development, Janssen Animal Health.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call